Luke Hakes

Luke Hakes has a diverse work experience that spans various roles and industries. In 2017, they became the Chairman of the University of Manchester Innovation Factory. In 2018, they joined both The University of Manchester and Seatfrog as an Investor and Non-Executive Director. Luke also served as a Member of the Global Leadership Board at The University of Manchester. In 2019, they took on the role of Investor and Non-Executive Director at the Medisafe® Medication Management Platform. In 2021, Luke Hakes expanded their portfolio by investing in multiple companies including Biofidelity, Imophoron Ltd, NanoSyrinx, and Overture Life, where they also served as an Investor and Non-Executive Director. In 2022, they worked as an Angel Investor. In 2023, they joined Lopay as an Investor and Non-Executive Director.

Luke Hakes' education history begins in 1998 when they enrolled at The University of Manchester to pursue a Bachelor of Science (BSc) degree in Biochemistry with Biotechnology. Luke completed this undergraduate program in 2002.

Following the completion of their BSc, Luke Hakes continued their education at The University of Manchester, where they pursued a Master of Science (MSc) degree in Bioinformatics from 2002 to 2003.

Luke Hakes then proceeded to further their studies at The University of Manchester, where they pursued a Doctor of Philosophy (PhD) degree in Computational Genetics from 2003 to 2006.

Throughout their education, Luke Hakes focused their studies in various disciplines related to genetics and computational biology, starting with biochemistry and biotechnology at the undergraduate level, followed by bioinformatics at the master's level, and finally specializing in computational genetics at the doctoral level.